Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Health Catalyst (HCAT) EBIT (2018 - 2025)

Health Catalyst's EBIT history spans 8 years, with the latest figure at -$86.1 million for Q4 2025.

  • For Q4 2025, EBIT fell 391.89% year-over-year to -$86.1 million; the TTM value through Dec 2025 reached -$160.9 million, down 130.43%, while the annual FY2025 figure was -$160.9 million, 130.43% down from the prior year.
  • EBIT reached -$86.1 million in Q4 2025 per HCAT's latest filing, down from -$17.5 million in the prior quarter.
  • In the past five years, EBIT ranged from a high of -$13.7 million in Q3 2024 to a low of -$86.1 million in Q4 2025.
  • Average EBIT over 5 years is -$32.1 million, with a median of -$32.6 million recorded in 2021.
  • Peak YoY movement for EBIT: soared 54.34% in 2024, then plummeted 391.89% in 2025.
  • A 5-year view of EBIT shows it stood at -$44.8 million in 2021, then increased by 17.92% to -$36.7 million in 2022, then increased by 10.78% to -$32.8 million in 2023, then skyrocketed by 46.62% to -$17.5 million in 2024, then tumbled by 391.89% to -$86.1 million in 2025.
  • Per Business Quant, the three most recent readings for HCAT's EBIT are -$86.1 million (Q4 2025), -$17.5 million (Q3 2025), and -$37.1 million (Q2 2025).